Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death

V W Y Lui1, E Y L Wong, K Ho

  • 1Cancer Signaling Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer, Chinese University of Hong Kong, Hong Kong, China.

Oncogene
|November 9, 2010
PubMed

Insights

c-Met tyrosine kinase inhibitors (TKIs) reduce nasopharyngeal cancer growth by downregulating TIGAR and depleting NADPH. This reveals a new therapeutic pathway targeting the tyrosine kinase/TIGAR/NADPH cascade in cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • c-Met is a key therapeutic target in various cancers.
  • Nasopharyngeal cancer (NPC) is an invasive head and neck cancer prevalent in Asia.
  • Understanding c-Met's mechanism in NPC is crucial for targeted therapy.

Purpose of the Study:

  • To elucidate the mechanism by which c-Met tyrosine kinase inhibition affects NPC growth and invasion.
  • To identify downstream targets of c-Met inhibition in NPC.
  • To explore the therapeutic potential of targeting the c-Met pathway in NPC.

Main Methods:

  • Utilized c-Met tyrosine kinase inhibitors (TKIs), AM7 and SU11274, in NPC cell lines.
  • Assessed c-Met phosphorylation, cell growth, invasion, TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) expression, and intracellular NADPH levels.
  • Investigated the effect of TIGAR overexpression on c-Met TKI-induced inhibition.

Main Results:

  • c-Met TKIs significantly downregulated c-Met phosphorylation, NPC cell growth, and invasion.
  • Inhibition of c-Met led to decreased TIGAR expression and subsequent depletion of intracellular NADPH.
  • Overexpression of TIGAR counteracted the inhibitory effects of c-Met kinase inhibition, confirming TIGAR's role.

Conclusions:

  • c-Met kinase inhibition impacts NPC via downregulation of TIGAR and subsequent NADPH depletion.
  • This study reveals a novel tyrosine kinase/TIGAR/NADPH signaling cascade.
  • Targeting this cascade presents a potential therapeutic strategy for human cancers, including NPC.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...